|Table of Contents|

Col6a1 boosts triple-negative breast cancer cell drug resistance and stemness

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2025 06
Page:
911-917
Research Field:
Publishing date:

Info

Title:
Col6a1 boosts triple-negative breast cancer cell drug resistance and stemness
Author(s):
YIN Ping; HU Yangyang; LIN Fanhong; HAN Dan; ZHANG Linjie
Department of Pathophysiology,College of Basic Medical Science,Clinical College of Anhui Medical University,Anhui Hefei 230031,China.
Keywords:
collagen type VI alpha 1（Col6a1）; triple-negative breast cancer; drug resistance; stemness
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2025.06.004
Abstract:
Objective:To analyze the expression of collagen type VI alpha 1 (Col6a1) in triple-negative breast cancer and its effect on drug resistance and stemness of triple-negative breast cancer cells.Methods:Bioinformatics method analyzed the effect of Col6a1 on the prognosis in triple-negative breast cancer,the expression of Col6a1 in triple-negative breast cancer cells and the relationship with the drug resistance-related protein ATP-binding cassette (ABC) superfamily G member 2 (ABCG2).Immunohistochemistry was used to detect the Col6a1 expression in triple-negative breast cancer tissues and non-triple-negative breast cancer tissues.The effect of Col6a1 on drug resistance in triple-negative breast cancer cells was examined by MTT assay.Mammosphere formation test was then used to evaluate the role of Col6a1 in triple-negative breast cell stemness.Results:Col6a1 was overexpressed in triple-negative breast cancer and was correlated with unfavorable prognosis.Col6a1 was overexpressed in triple-negative breast cancer tissues and cells.Col6a1 was positively correlated with ABCG2.Col6a1 knockdown enhanced the sensitivity of MDA-MB-231 cells and Hs 578T cells to paclitaxel(PTX) and impaired mammosphere formation capacity of these two cell lines.Conclusion:Col6a1 contributes to triple-negative breast cancer cells drug resistance and stemness,and can be a potential target for the treatment of triple-negative breast cancer.

References:

［1］MICHAELS E,CHEN N,NANDA R.The role of immunotherapy in triple-negative breast cancer (TNBC)［J/OL］.Clinical Breast Cancer,2024［2024-04-24］.Advance Online Publication.https://pubmed.ncbi.nlm.nih.gov/38582617/.DOI:10.1016/j.clbc.2024.03.001.
［2］YAN LJ,Y LAU AT,XU YM.The regulation of microRNAs on chemoresistance in triple-negative breast cancer:a recent update［J/OL］.Epigenomics,2024［2024-04-24］.Advance Online Publication.https://pubmed.ncbi.nlm.nih.gov/38639712/.DOI:10.2217/epi-2023-0430.
［3］KAZIMIR A,GOTZE T,LONNECKE P,et al.Exploring raloxifene-based metallodrugs:A versatile vector combined with Pt(II),palladium(II) and nickel(II) dichlorides and carborates against triple-negative breast cancer［J/OL］.Chem Med Chem,2024［2024-04-24］.Advance Online Publication.https://pubmed.ncbi.nlm.nih.gov/38642018/.DOI:10.1002/cmdc.202400006.
［4］QU B,LI X,MA Y,et al.68Ga labeled EphA2-targeted cyclic peptide:a novel positron imaging tracer for triple-negative breast cancer［J/OL］.Dalton Transactions,2024［2024-04-24］.Advance online publication.https://pubmed.ncbi.nlm.nih.gov/38646723/.DOI:10.1039/d4dt00837e.
［5］KIM K,KIM YJ.RhoBTB3 regulates proliferation and invasion of breast cancer cells via Col1a1［J］.Molecules and Cells,2022,45(9):631-639.
［6］MARTINS CAVACO AC,DAMASO S,CASIMIRO S,et al.Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis［J］.Cancer Metastasis Reviews,2020,39(3):603-623.
［7］LIU J,SHEN JX,WU HT,et al.Collagen 1A1 (COL1A1) promotes metastasis of breast cancer and is a potential therapeutic target［J］.Discovery Medicine,2018,25(139):211-223.
［8］BALTES F,CASPERS J,HENZE S,et al.Targeting discoidin domain receptor 1 (DDR1) signaling and its crosstalk with β1-integrin emerges as a key factor for breast cancer chemosensitization upon collagen type 1 binding［J］.International Journal of Molecular Sciences,2020,21(14):4956.
［9］GIUSSANI M,LANDONI E,MERLINO G,et al.Extracellular matrix proteins as diagnostic markers of breast carcinoma［J］.Journal of Cellular Physiology,2018,233(8):6280-6290.
［10］XIONG G,DENG L,ZHU J,et al.Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen deposition［J］.BMC Cancer,2014,14:1.
［11］WEI LY,HANG XJ,WANG L,et al.A six-epithelial-mesenchymal transition gene signature may predict metastasis of triple-negative breast cancer［J］.OncoTargets and Therapy,2020,13:6497-6509.
［12］YIN P,BAI Y,WANG Z,et al.Non-canonical Fzd7 signaling contributes to breast cancer mesenchymal-like stemness involving Col6a1［J］.Cell Communication and Signaling,2020,18(1):143.
［13］LANCZKY A,NAGY A,BOTTAI G,et al.miRpower:a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients［J］.Breast Cancer Research and Treatment,2016,160(3):439-446.
［14］DONG X,BAI X,NI J,et al.Exosomes and breast cancer drug resistance［J］.Cell Death & Disease,2020,11(11):987.
［15］CHANDRATRE S,OLSEN J,HOWLEY R,et al.Targeting ABCG2 transporter to enhance 5-aminolevulinic acid for tumor visualization and photodynamic therapy［J］.Biochemical Pharmacology,2023,217:115851.
［16］PENA-SOLORZANO D,STARK SA,KONIG B,et al.ABCG2/BCRP:Specific and nonspecific modulators［J］.Medicinal Research Reviews,2017,37(5):987-1050.
［17］NOGUCHI K,KATAYAMA K,MITSUHASHI J,et al.Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy［J］.Advanced Drug Delivery Reviews,2009,61(1):26-33.
［18］YIN P,WANG W,GAO J,et al.Fzd2 contributes to breast cancer cell mesenchymal-like stemness and drug resistance［J］.Oncology Research,2020,28(3):273-284.
［19］徐飞，石峰，王军，等.miR-520a-3p靶向ABCG2增强乳腺癌细胞对多西他赛敏感性的机制研究［J］.现代肿瘤医学，2019,27（14）：2488-2493. XU Fei,SHI Feng,WANG Jun,et al.miR-520a-3p enhances the sensitivity of human breast cancer cells to docetaxel by suppressing ABCG2 expression［J］.Modern Oncology,2019,27（14）：2488-2493.
［20］WESTOVER D,LI F.New trends for overcoming ABCG2/BCRP-mediated resistance to cancer therapies［J］.Journal of Experimental & Clinical Cancer Research,2015,34:159.
［21］PRASAD S,RAMACHANDRAN S,GUPTA N,et al.Cancer cells stemness:A doorstep to targeted therapy［J］.Biochimica Et Biophysica Acta.Molecular Basis of Disease,2020,1866(4):1654249.
［22］DRAGU DL,NECULA LG,BLEOTU C,et al.Therapies targeting cancer stem cells:Current trends and future challenges［J］.World Journal of Stem Cells,2015,7(9):1185-1201.
［23］ZHU P,FAN Z.Cancer stem cells and tumorigenesis［J］.Biophysics Reports,2018,4(4):178-188.
［24］HOU T,TONG C,KAZOBINKA G,et al.Expression of COL6A1 predicts prognosis in cervical cancer patients［J］.American Journal of Translational Research,2016,8(6):2838-2844.
［25］ZHANG X,LIU J,YANG X,et al.High expression of COL6A1 predicts poor prognosis and response to immunotherapy in bladder cancer［J］.Cell Cycle,2023,22(5):610-618.
［26］ZHANG Y,LIU Z,YANG X,et al.H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts［J］.Theranostics,2021,11(3):1473-1492.
［27］ZHANG Y,LIU Z,YANG X,et al.Erratum:H3K27 acetylation activated-COL6A1 promotes osteosarcoma lung metastasis by repressing STAT1 and activating pulmonary cancer-associated fibroblasts:Erratum［J］.Theranostics,2022,12(10):4604-4605.
［28］OWUSU-ANSAH KG,SONG G,CHEN R,et al.COL6A1 promotes metastasis and predicts poor prognosis in patients with pancreatic cancer［J］.International Journal of Oncology,2019,55(2):391-404.
［29］HAN X,WANG Q,FANG S,et al.P4HA1 regulates CD31 via COL6A1 in the transition of glioblastoma stem-like cells to tumor endothelioid cells［J］.Frontiers in Oncology,2022,12:836511.
［30］XIN S,FANG W,LI J,et al.Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients［J］.Journal of Cancer Research and Clinical Oncology,2021,147:725-737.
［31］LI N,LIU M,CAO X,et al.Identification of differentially expressed genes using microarray analysis and COL6A1 induction of bone metastasis in non-small cell lung cancer［J］.Oncology Letters,2021,22(4):693.

Memo

Memo:
安徽医科大学临床医学院校级科研项目（编号：2023XJKY001）
Last Update: 1900-01-01